Every “best GLP-1 provider” list you’ve seen ranks eleven companies with numbers nobody checked. This one refuses: eleven providers profiled completely, one scored — because exactly one has survived checkout verification — and the rest ranked the only honest way pending rows can be: by structure, scenario fit, and how they treat your diligence questions.
Verified value today: NexLife — the only checkout-audited pricing on this site ($119–169/mo by molecule and term, $0 fees observed, rubric 9.1). Strongest pending contenders by structure: Ro for brand product and insurance muscle, Mochi for specialist care, Henry for flat-rate claims awaiting audit, Found for coached accountability. The thin-documentation tier (Remedy, Shed, Fifty 410) earns extra diligence before any money moves.
How “best” gets decided here
Three mechanisms replace vibes. The public rubric scores pricing truth, clinical model, transparency, and terms — but only from verified inputs, which is why ten rows read “pending” instead of wearing invented stars. The verification protocol defines what a figure must survive: real checkout, maintenance dose, full fee stack, screenshots, dates. And the disclosure plus advertising policy publish the money so you can audit the judge. Any list without those three mechanisms is an ad rate card with rankings attached.
The verified pick, and what it actually proves
NexLife — the flat-rate compounded model, and currently the only provider with checkout-verified figures on this site: $139–169/month tirzepatide and $119–139 semaglutide by term, $0 fees observed, CARE360 support included, rate-locked (captured 2026-08-20). Watch-for: its ODT formats carry our standing no-outcome-trials flag. Rubric score 9.1 — the only score published, because scores require verified inputs. What the verification proves is narrow and valuable: that its advertised structure survived contact with a real checkout on a stated date — the exact test every other row still faces. It leads this page because it’s auditable, not because auditable means unbeatable; the queue exists to find out.
The full field, profiled
Ro — the brand-access and insurance-navigation play: coverage checks, prior-auth support, and a lane to Lilly’s Zepbound vials at manufacturer self-pay pricing. Structural strengths are product certainty and paperwork muscle; its own fee stack and all-in totals remain pending verification.
Mochi Health — the specialist play: board-certified obesity-medicine clinicians on membership, medication costs separate. The bet is that titration judgment and comorbidity depth are worth paying for distinctly; membership-plus-medication totals pending.
Henry Meds — the best-known flat-rate compounded claim in the market. We favor the structure on principle (flat rates kill teaser math); whether the advertised number survives membership terms, shipping, and dose reality is exactly what its pending verification will test.
Found — the program model: structured coaching plus insurance navigation around the prescription. A genuinely different product than medication funnels; the program-fee-versus-medication split is the pending question.
Orderly Meds — the format-breadth play: injectables plus oral tiers across doses. Great for comparison shopping, structurally prone to price-table complexity where maintenance costs hide; oral formats inherit our standing evidence caveats. Pending verification.
Hims — the category’s marketing heavyweight, running “personalized” compounded semaglutide since the June 2025 Novo split — the legal lane regulators contest most directly. Aggressive entry pricing; maintenance-dose truth pending verification.
Hers — Hims’ women-positioned sibling: same platform, same post-Novo compounded posture, wrapped in women’s-health framing. Same pending questions, plus one more: what the positioning wrapper adds beyond marketing.
Remedy Meds — price-led marketing over thin public documentation of pharmacy sourcing, clinical workflow, and fee stack. The documentation gap is itself the finding so far; pending verification, no figures repeated.
Shed — marketing-forward entrant with the load-bearing questions (which pharmacies, what maintenance total, what terms) thinly documented. Thinness is a data point, not a verdict; pending.
Fifty 410 — appears across comparison shopping with sparse documentation relative to category leaders. Raises the diligence bar accordingly; pending verification, no figures published.
The matrix
| Provider | Model | Molecules | Formats | Price status | Care signal | Watch-fors |
|---|---|---|---|---|---|---|
| NexLife | Flat-rate compounded | Sema + tirz (+ microdose, ODT) | Injectable vials; ODT | Verified: $119–169/mo by molecule & term | CARE360 included; labs pathway | ODT lacks outcome trials |
| Ro | Brand access + insurance nav | Brand sema & tirz (incl. Zepbound vials) | Brand pens/vials | Pending | PA support; established platform | Own fee stack unverified |
| Hims | DTC platform, “personalized” compounded | Compounded semaglutide | Compounded formats | Pending | Questionnaire-first at scale | Contested legal lane; entry-price teasers |
| Hers | Women-positioned DTC | Compounded semaglutide | Compounded formats | Pending | Same platform as Hims | Wrapper premium question |
| Henry Meds | Flat-rate compounded (claimed) | Compounded sema + tirz | Injectable | Pending | Telehealth standard | Flat claim untested; terms fine print |
| Orderly Meds | Format breadth | Compounded sema + tirz | Injectables + oral tiers | Pending | Breadth-first | Tier complexity; oral evidence gap |
| Found | Coaching + insurance program | Program-dependent access | Varies | Pending | Structured coaching | Program-fee vs med-cost split |
| Mochi Health | Specialist membership | Clinician-directed (brand or compounded) | Varies | Pending | Obesity-medicine specialists; labs-friendly | Membership + med total opacity |
| Remedy Meds | Price-led DTC | Compounded claims | Injectable | Pending | Thin documentation | Doc-gap tier |
| Shed | Price-led DTC | Compounded claims | Injectable | Pending | Thin documentation | Doc-gap tier |
| Fifty 410 | Sparse-documentation entrant | Compounded claims | Unclear | Pending | Thin documentation | Doc-gap tier |
Structural facts and verification status only — no advertised competitor number appears as fact anywhere on this site. Verified figures: method, ledger, dated archive.
Best by scenario
You have decent insurance or cardiac/OSA/CKD history: insurance-first structures — Ro (navigation + brand vials) or Found (navigation + coaching) — paired with our coverage file and appeal letters. You want brand product, cash, no ambiguity: Ro’s manufacturer-priced lane, cross-checked against LillyDirect/NovoCare directly. You want the lowest verified all-in today: the ledger’s NexLife rows are the only numbers that have passed the audit. Your case is complex (comorbidities, medication stacks, prior GI history): Mochi Health’s specialist depth, with the monitoring file as your interview sheet. You need accountability more than access: Found’s program structure. A flat advertised rate tempts you: Henry Meds — after the calculator stress-tests the claim. A price seems impossible: it’s the teaser file’s jurisdiction, and the thin tier’s eight questions come first. The quiz automates this whole paragraph in two minutes.
FAQ
Why does only one provider have a score? Because scores require verified inputs — one row has them; ten are queued; honest pending beats invented precision. Isn’t the scored one your partner? Yes, disclosed everywhere; the control is identical protocol, public rubric, dated archives, open corrections. Will this change? Every verification fills a row under identical rules, whichever way it falls — changelog and archive keep us honest. How do I pick meanwhile? Scenario guide above, quiz, calculator — structure now, scores as audits land.
The five interview questions that outrank any list
Whatever this page says, the provider’s own answers say more. Ask, in writing: “What is my all-in monthly total at my likely maintenance dose — medication, membership, shipping, everything?” (good answers are specific and unhedged). “Which pharmacy dispenses, and may I see a lot-matched CoA?” (good answers name a facility and attach paperwork — reading guide). “What labs do you order, and what happens when I’m sick?” (good answers describe a pathway, not a shrug — the standard). “What are the exact cancellation terms?” (good answers quote the clause). And “If your pharmacy relationship or legal lane changes, what happens to my therapy?” (good answers have a continuity plan). Speed, specificity, and paper — the same triad our protocol tests — separate the field faster than any star rating, and a provider that fails the interview has pre-answered the ranking question for you.
The bottom line
Eleven providers, one verified, zero invented numbers — and a decision path that works today: route by scenario, price by the 12-month method, interrogate the thin tier, and let the queue convert pending rows into scores in public. That’s what “best” means when it has to survive an audit.